Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ(TM) in Leptomeningeal Metastases

Stock Information for Co-Diagnostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Co-Diagnostics Inc.

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ(TM) in Patients with Leptomeningeal Metastases
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ(TM) in Leptomeningeal Metastases
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.